4205-05-4

Usage

InChI:InChI=1/C9H7ClN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-6H,(H,11,12)

Upstream product

• 108-90-7 chlorobenzene 
• 50846-98-5 2-Diazo-2H-imidazole 
• 13623-52-4 2-(4-chlorophenyl)-2-imidazoline 
• 623-03-0 4-Cyanochlorobenzene 
• 27429-86-3 2-(3-chlorophenyl)-4,5-dihydro-1H-imidazole 
• 122-01-0 4-chloro-benzoyl chloride 
• 107-15-3 ethylenediamine 
• 288-32-4 1H-imidazole 
• 106-47-8 4-chloro-aniline 
• 131543-46-9 Glyoxal 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 65004-59-3 2-(4-chlorophenyl)-4-chlorosulfonylimidazole 
• 1160826-45-8 C₁₆H₁₀ClN₃O₃ 
• 1160826-53-8 C₁₆H₁₀BrClN₂O 
• 1253697-54-9 2-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-imidazole 
• 1253697-97-0 ABI-286 
• 1253697-73-2 (2-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 

Relevant academic research and scientific papers

NOVEL IMIDAZOLE DERIVATIVE, AND ORGANIC EL ELEMENT PREPARED THEREWITH

PROBLEM TO BE SOLVED: To provide a novel imidazole derivative that emits light with high efficiency, and an organic EL element prepared therewith. SOLUTION: The present invention provides a benzoimidazophenanthridine compound represented by the following

Synthesis, antimicrobial activities and binding mode analysis of some novel N-substituted imidazoles and nitroimidazoles

Novel N-((2-(aryl)-imidazol-1-yl) methyl)-anilines 2a-n and 1-(3'-arylamino-2'- hydroxypropyl)-2-methyl-4-nitroimidazoles 4a-g have been synthesized. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their antibacterial activities. Among the synthesized compounds, compounds 2m, 2n and compounds 4c, 4e exhibited highest inhibitory activity against all the bacterial strains, comparable to the standard drug ciprofloxacin. Binding mode analysis of the highest active compounds was carried out in the active site of GlcN-6-P synthase (2VF5).

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Multi-wall carbon nanotube supported manganese(III) porphyrin: An efficient and reusable catalyst for oxidation of 2-imidazolines with sodium periodate

The oxidation of 2-substituted imidazolines with sodium periodate catalyzed by tetrakis(p-aminophenyl)-porphyrinatomanganese(III) chloride, [Mn(TNH 2PP)Cl], supported on functionalized multi-wall carbon nanotubes is reported. A wide variety of 2-imidazolines were efficiently converted to their corresponding imidazoles by this catalytic system. When the same reaction was subjected to ultrasonic irradiation, the reaction times were reduced significantly and the product yields were increased. This catalyst could be reused several times without significant loss of activity. The effects of reaction parameters such catalyst amount, choice of solvent, and the effects of ultrasonic irradiation on the catalytic activity have been investigated.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones

A series of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones (111) were synthesized and screened for their antimicrobial and antimycobacterial activities. Further, a series of [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones (1220) reported in our earlier study was also screened for their antimycobacterial activity. The antimycobacterial activity results indicated that [2-(4-Nitro-phenyl)-imidazol- 1-yl]-pyridin-3-yl-methanone (8, minimum inhibitory concentration [MIC]=3.13 g) was equipotent as standard drug ciprofloxacin and [2-(4-Nitro-phenyl)- benzimidazol-1-yl]-pyridin-3-yl-methanone (16, MIC=1.56 g) was equipotent as standard drug ethambutol. The results of antimicrobial screening demonstrated that 2-[1-(Pyridine-3-carbonyl)-1H-imidazol-2-yl]-benzoic acid (compound 11, MIC=0.002 g) was two times more effective than standard drug ciprofloxacin (MIC=0.004 g) against tested bacterial strains and [2-(2,5-Dimethyl-phenyl)- imidazol-1-yl]-pyridin-3-yl-methanone (compound 3, MIC=0.005 g) was equipotent to the reference compound, fluconazole against tested fungal strains.

Rapid and efficient biomimetic oxidation of 2-imidazolines to their corresponding imidazoles with NaIO4 catalyzed by Mn(salophen)Cl

Rapid and efficient oxidation of 2-substituted imidazolines with sodium periodate is reported. The Mn(III)-salophen/NaIO4 catalytic system efficiently converted 2-imidazolines to their corresponding imidazoles at room temperature in 2: 1, CH3CN/H2O mixture.

Oxidation of 2-imidazolines to 2-imidazoles with sodium periodate catalyzed by polystyrene-bound manganese(III) porphyrin

In the present work, the dehydrogenation of 2-substituted imidazolines with sodium periodate in the presence of tetraphenylporphyrinatomanganese(III) chloride supported on polystyrene-bound imidazole, [Mn(TPP)Cl@PSI] is reported. A wide variety of 2-imidazolines were efficiently converted to their corresponding imidazoles by the [Mn(TPP)Cl@PSI]/NaIO4 catalytic system in a 1:2 CH3CN/H2O mixture under agitation with magnetic stirring. Ultrasonic irradiation enhanced the catalytic activity of this catalyst in the oxidation of 2-imidazolines and this led to shorter reaction times and higher product yields. This catalyst could be reused several times without significant loss of its catalytic activity.

Dehydrogenation of 2-imidazolines with sodium periodate catalyzed by manganese(III) tetraphenylporphyrin

In the present work, dehydrogenation of 2-substituted imidazolines with sodium periodate in the presence of tetraphenylporphyrinatomanganese(III) chloride, [Mn(TPP)Cl], is reported. A wide variety of 2-imidazolines efficiently converted to their corresponding imidazoles by [Mn(TPP)Cl]/NaIO4 catalytic system at room temperature in 1:2, CH3CN/H2O mixture. The effect of reaction parameters such as kind of solvent and catalyst amount was also investigated.

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents

A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4- carboxylic amide (AICA) derivatives and 4-substituted methoxylbenzoyl-aryl- thiazoles (SMART). The average IC50 of the most active compound (5da) was 15.7 nM. ABI analogues have substantially improved aqueous solubility (48.9 μg/mL for 5ga vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4). Mechanism of action studies indicate that the anticancer activity of ABI analogues is through inhibition of tubulin polymerization by interacting with the colchicine binding site. Unlike paclitaxel and colchicine, the ABI compounds were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells. In vivo results indicated that 5cb was more effective than DTIC in inhibiting melanoma xenograph tumor growth. Our results suggest that the novel ABI compounds may be developed to effectively treat drug-resistant tumors.